Lyophilised vs non-lyophilised peptides

Two phrases do a great deal of quiet work in research peptide listings: lyophilised and non-lyophilised. The first means freeze-dried — the peptide is supplied as a dry solid, the familiar white cake or fine powder sealed in a glass vial. The second is defined by negation: the peptide was not freeze-dried, and the vial contains it already dissolved, as a solution. British suppliers write lyophilised; American ones write lyophilized (the US spelling — the two denote exactly the same process, and search results mix them freely). Behind the spelling sits a single, consequential difference of physical form, and it is worth decoding properly, because almost everything about how a peptide behaves as a stock material — how it degrades, how long it lasts, how it ships and how its quantity is verified — follows from whether the water is in the vial or out of it.

This guide is the comparison: what lyophilisation of peptides actually involves, what a non-lyophilised product is, and why the solid form so completely dominates research supply. It sits alongside our guide to lyophilised peptide storage, which covers the conditions that keep the solid form stable once it is on the shelf; this page is about the choice of form itself. The frame throughout is the laboratory: everything NorthScientific supplies is for research use only, and peptides here are reagents, nothing else.

What lyophilisation of peptides involves

Lyophilisation is the formal name for freeze-drying, and the process rests on one corner of water’s phase diagram. Hold ice cold enough, under a deep enough vacuum, and warming it produces no liquid at all: the ice sublimes, converting straight to vapour and leaving whatever was dissolved in the frozen solution behind as an open, porous solid. A freeze-drier walks a batch of filled vials through exactly that route. The purified peptide solution — the pooled output of preparative chromatography — is frozen hard, the chamber is pumped down to a small fraction of atmospheric pressure, and just enough heat is supplied to keep sublimation going without ever letting liquid water reappear. A gentler final stage then draws off the last traces of water held by the peptide molecules themselves, and each vial is closed over a cake carrying around one per cent water by weight.

Two details matter for the comparison to come. First, freeze-drying is gentle by design. Sublimation happens cold, so the peptide never meets the temperatures that evaporative drying would demand, and the molecule emerges chemically unchanged — the same sequence, the same mass, minus the water. Second, it is a deliberate extra manufacturing step with real cost in equipment and cycle time, performed on almost everything in the research trade anyway because of what it buys. The full production sequence — synthesis, cleavage, purification, then peptide lyophilisation as the closing step — is covered in how research peptides are made.

What non-lyophilised actually means

Interest in the phrase usually comes from someone comparing listings — what does non-lyophilised mean when a supplier prints it? — and the answer is plainer than the word suggests. A non-lyophilised peptide is one supplied in solution: the freeze-drying step was skipped, and the vial holds the peptide dissolved in an aqueous liquid at some stated concentration. Since every synthetic peptide is in solution at the moment purification finishes, non-lyophilised is not an alternative technology. It is the same manufacturing sequence stopped one step early, with the water left in.

Solution formats do have a legitimate niche. Certified reference standards for analytical instruments are sometimes sold as solutions at a stated concentration, because a ready solution suits an autosampler — but those products are built around short validated lifetimes, cold-chain dispatch and an expiry date measured in months, and they are priced accordingly. Where non-lyophilised appears in a general peptide listing without that scaffolding, the offer is simply the same molecule with the water still in the vial — and the rest of this guide is an account of what the water costs.

The chemistry: why the water matters

Peptide degradation runs on a short list of well-characterised pathways — backbone hydrolysis, deamidation, oxidation and aggregation — and water is implicated in all of them. It is a direct reagent in hydrolysis and deamidation, cleaving amide bonds and converting asparagine side chains; it is the medium that carries dissolved oxygen and trace metal ions to oxidisable residues; and it is the solvent in which molecules drift into contact, unfold and associate into aggregates. In solution every one of these routes runs continuously, at rates set by temperature, pH and sequence. An aqueous peptide solution is also, bluntly, a growth medium: unless it is preserved or handled sterile, microbial contamination joins the list.

Freeze-drying removes the reagent and the medium in one operation. In a dry cake the water-dependent chemistry — hydrolysis, deamidation — goes essentially dormant, because those reactions have lost both their reagent and the solvent they run in; aggregation is suppressed along with them, since molecules fixed in a solid matrix cannot find one another. The honest caveat is oxidation: headspace oxygen can still work slowly on methionine, cysteine and tryptophan even in a dry solid, which is why the seal and the dark still matter after freeze-drying — ground covered properly, along with the full degradation map, in the storage and stability guide. The comparison remains directional and stark. Lyophilisation silences the dominant pathways outright and slows the remainder to a crawl, where the best refrigeration can do for a solution is make every pathway somewhat slower — which is why a sealed solid held cold and dark stays close to its release state for years, while the same peptide in solution measurably ages over weeks to months.

Weighing, labels and verification

A solid can be weighed, and that single fact does more work than it appears to. When a label on a lyophilised vial states 10 mg, it is making a gravimetric claim about a physical solid — a quantity of matter that was dispensed on a balance and could in principle be checked on one. The honest caveat is that the stated mass is the mass of the lyophilised material, which includes counter-ions and residual moisture as well as peptide; the difference between gross mass and actual peptide is the subject of peptide purity vs net peptide content, and it applies to every supplier’s solid equally.

A solution offers no such anchor. Its label states a concentration, and a concentration cannot be checked with a balance — verifying it requires a quantitative assay against a standard. Worse, it is a moving target: because degradation chemistry runs continuously in solution, the true concentration of intact peptide is highest on the day of filling and lower on every day after, at a rate the buyer cannot see. A solid that has been stored sealed and cold can be assayed years later against its release data; a solution’s release data begins going stale in transit.

Shipping and shelf life

Transit is where the two forms diverge most visibly. For the solid the question is essentially settled — a sealed, dry cake ages so slowly at ambient temperature that a courier’s few days barely register, which is why lyophilised vials travel without refrigeration as a matter of routine; the kinetics behind that are set out in the storage guide.

A solution enjoys no such margin. Its clock runs at full speed at room temperature, so every warm day in a van is real chemical ageing, and what arrives is older — in the sense that matters — than what was filled. The standard remedy is cold-chain logistics: insulated packaging, gel packs or dry ice, temperature indicators, and a shipment that is heavier, costlier and fallible at every handover. Nor is deliberately freezing the solution a free option, because freeze–thaw cycling is itself a recognised physical stress that promotes aggregation; a solution frozen and thawed en route can arrive worse off than one kept merely cool. Where non-lyophilised material is offered without this scaffolding, the transit problem has not been solved — it has been ignored.

NorthScientific supplies the solid form only. Parcels leave UK stock as sealed lyophilised vials — dispatch details are under shipping — and on arrival the material goes to the freezer as supplied.

Reading a catalogue listing

The vocabulary, once decoded, tells you most of what you need. Lyophilised powder in a sealed vial is the stability-engineered default of the research trade; a non-lyophilised listing is offering the same molecule with the manufacturing sequence stopped a step early, and should come with the cold-chain logistics and dated assay that a solution honestly requires. Everything in the NorthScientific catalogue is supplied the first way: lyophilised powder in crimp-sealed glass vials, with the label mass stating the lyophilised content — BPC-157 at 10 mg per vial, GHK-Cu at 50 mg, TB-500 at 10 mg. Storage conditions for the solid form are on each product page, and the reasoning behind them is one guide away.

Materials referenced: BPC-157 · GHK-Cu · TB-500 · full catalogue